Pfizer: phase 3 endpoint achieved in haemophilia
(CercleFinance.com) - Pfizer announced on Tuesday that its investigational drug marstacimab had met its primary endpoints in a phase 3 clinical trial for the treatment of severe A or B haemophilia.
The global study showed that the human monoclonal immunoglobulin reduced bleeding episodes by 92% in 116 patients followed for one year.
This is the third phase 3 program that is currently being conducted by Pfizer in severe haemophilia A or B, in addition to the gene therapies fidanacogene elaparvovec and giroctocogene fitelparvovec.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The global study showed that the human monoclonal immunoglobulin reduced bleeding episodes by 92% in 116 patients followed for one year.
This is the third phase 3 program that is currently being conducted by Pfizer in severe haemophilia A or B, in addition to the gene therapies fidanacogene elaparvovec and giroctocogene fitelparvovec.
Copyright (c) 2023 CercleFinance.com. All rights reserved.